Drugs that contain Rufinamide
1. Banzel patents expiration
BANZEL Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(1 year, 5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8076362 | EISAI INC | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof |
Jun, 2018
(5 years ago) | |
| US7750028 | EISAI INC | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
Oct, 2018
(5 years ago) | |
|
US8076362 (Pediatric) | EISAI INC | Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof |
Dec, 2018
(5 years ago) | |
|
US7750028 (Pediatric) | EISAI INC | Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide |
Apr, 2019
(5 years ago) | |
|
US6740669 (Pediatric) | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
May, 2023
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | May 14, 2016 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2013 |
| Orphan Drug Exclusivity(ODE) | Nov 14, 2015 |
NCE-1 date: 15 May, 2015
Market Authorisation Date: 14 November, 2008
Treatment: Treatment of epilepsy
Dosage: TABLET;ORAL; SUSPENSION;ORAL
How can I launch a generic of BANZEL before it's drug patent expiration?
More Information on Dosage
BANZEL family patents
